Trials / Completed
CompletedNCT00001489
Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism
The Effect of Vigabatrin on Cerebral Blood Flow and Glucose Metabolism
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (planned)
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS) · NIH
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is designed to test the effects of vigabatrin (gamma-vinyl-GABA) an experimental drug used for the treatment of epilepsy. The study will use positron emission tomography (PET scan) to detect areas of the brain receiving increased blood flow and using increased amounts of glucose. Increases in blood flow and glucose use are good indicators of brain activity. Researchers are interested in determining the effects of Vigabatrin on brain blood flow and glucose use.
Detailed description
This double-blind placebo-controlled parallel design protocol will investigate the effects of gamma-vinyl-GABA (vigabatrin--GVG) an experimental antiepileptic drug, on cerebral glucose metabolism (LCMRglc), blood flow (CBF), and seizure frequency, in patients with uncontrolled complex partial (CPS) and secondary generalized seizures (GTCS). Positron Emission Tomography (PET) will be used to measure CBF and LCMRglc.
Conditions
Timeline
- Start date
- 1994-10-01
- Completion
- 2000-08-01
- First posted
- 2002-12-10
- Last updated
- 2008-03-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00001489. Inclusion in this directory is not an endorsement.